155 related articles for article (PubMed ID: 15297187)
21. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
22. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
23. p53 tumoral supressor gene expression and significance in endometrial cancer.
Lazăr E; Lazăr DC
Rom J Morphol Embryol; 1998; 44(1-4):125-32. PubMed ID: 15678853
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
[TBL] [Abstract][Full Text] [Related]
25. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
26. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
27. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
28. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Engelsen IB; Stefansson I; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2006 Oct; 195(4):979-86. PubMed ID: 16677592
[TBL] [Abstract][Full Text] [Related]
29. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
31. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases.
Trahan S; Têtu B; Raymond PE
Hum Pathol; 2005 Dec; 36(12):1316-21. PubMed ID: 16311126
[TBL] [Abstract][Full Text] [Related]
32. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
34. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
35. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis.
Li SS; Xue WC; Khoo US; Ngan HY; Chan KY; Tam IY; Chiu PM; Ip PP; Tam KF; Cheung AN
Histopathology; 2005 Mar; 46(3):307-13. PubMed ID: 15720416
[TBL] [Abstract][Full Text] [Related]
36. WT1 expression correlates with angiogenesis in endometrial cancer tissue.
Dohi S; Ohno S; Ohno Y; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2010 Aug; 30(8):3187-92. PubMed ID: 20871039
[TBL] [Abstract][Full Text] [Related]
37. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
Acs G; Pasha T; Zhang PJ
Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
39. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
40. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
